Click here to download

About The Pharmaceutical Strategy Series
The Pharmaceutical Strategy Series produces executive-level conferences that bring together R&D leaders and corporate executives to assess business opportunities, enhance corporate value, and forecast the economic and regulatory landscape within the rapidly changing pharmaceutical & biotechnology industries.

PSS conferences are uniquely designed to maximize peer-to-peer networking and idea sharing. Conference topics are chosen based on attendee feedback and advice given by the PSS Advisory Board, which is comprised of decision-makers at most of the world's leading pharmaceutical companies. Presentations in each Executive Conference will give you the ideas, information, and resources you need to make faster and smarter decisions.

The Pharmaceutical Strategy Series is a division of Cambridge Healthtech Institute.

Sixth Annual
R&D Risk Mitigation and Value Creation Strategies
March 25-27, 2008 • San Francisco, California
a part of the 15th Annual Molecular Medicine Tri-Conference
Program  |  Register  |  Download

Re-engineering of Translational and Clinical Medicine
April 1-3, 2008 • Hydrabad, India

Second Annual
Alliance Management Congress
April 9-11, 2008 • Philadelphia, Pennsylvania
Program  |  Register  |  Download

  • How to Start and Build the Alliance Management Function
  • ‘Point-Counterpoint’: Where and in Which Function Does the Alliance Management Responsibility Reside?
  • Failed and Successful Alliances: What Went Wrong, How Addressed and Aftermath
  • Project Management & Alliance Management Connections
  • Strategic Recommendations for Contracting and Re-Negotiating Alliance Contracts
  • Pharmacovigilance and Labeling in Alliances

  • Building a Global Presence through Alliances
  • Managing Virtual Alliances
  • Developing Alliances between Big Pharma & Major Academic Centers
  • Can Innovation Exist in Alliance Management?

Second Annual
Global R&D Congress
Strategic Planning for Discovery, Development and Clinical Operations in China, India and other Emerging Regions
May 29-30, 2008 • The Ritz-Carlton • Washington, D.C.
Program  |  Register 
  • Understanding IP barriers and trends when planning a global strategy in India, China and other markets 
  • Best approaches to outsourcing, in-licensing, out-licensing, and risk sharing partnerships 
  • Examining the regulatory landscape of Asia, Eastern Europe and Latin America 
  • Clarifying the business, regulatory and research environment for drug discovery, drug development and clinical research 
  • Managing complicated and long-distance collaborative third-party relationships 
  • Overcoming the logistical challenges of transferring technology and data, and training staff 
  • Embracing and integrating the opportunities of emerging regions through innovative strategies and flexible approaches 
  • Sourcing the globe for the best in discovery and development services and partners 
  • Strategic planning for clinical development operations 

Third Annual
Drug Development China
Strategies for Launching Discovery and Development Activities
September 17-18, 2008 • The Fairmont • San Francisco, CA
Program  |  Register

  • Integrating Intellectual Property Management and Regulatory Compliance 
  • Understanding Key Drivers so to Best Leverage Emerging Markets to Develop Novel Drugs 
  • In-Licensing, Out-Licensing, and Risk Sharing: The China Landscape for Partnership Deals
  • Opportunities for Drug Discovery in China (Chemistry, Biology, Integrated Projects)
  • Why Conducting Preclinical Work in China is the Future
  • Strategic Planning for Clinical Development Operations in China 

The role of the Advisory Board is to assist CHI in identifying those issues which are seminal to decision-making in today's challenging world of drug development with the expressed intention of creating a forum for dialogue, constructive debate, and shared learning within the industry."

Richard M. Bayney, Ph.D., 
Vice President, Decision Analysis & Portfolio Management, PRD,
Johnson & Johnson

For partnering and sponsorship information, please contact:

Arnie Wolfson
Manager, Business Development
Pharmaceutical Strategy Series
Cambridge Healthtech Institute
T: 781.972.5431

Other Series:
Drug Development, Informatics, Genomics, Chemistry, Diagnostic

Richard M. Bayney, Ph.D.
Vice President, Decision Analysis and Portfolio, Management, PRD
Johnson & Johnson

Balu Balasubramanian, Ph.D.,
Executive Director, Research and Development, Bristol-Myers Squibb Co.

Matt Bell, Ph.D., MA
Senior Director, Discovery Research Strategy, Wyeth

Dennis Engers
International Director, Preclinical Planning and Resource Management, sanofi-aventis

Rainer Fuchs, Ph.D.
Co-Head Discovery Research
Vice President, Research Informatics,
Biogen Idec Inc.

Richard Heaslip, Ph.D.
Vice President, Project and Portfolio Management,

Shama Kajiji, Ph.D., MBA
Director, Portfolio Franchise Management Department,
Merck and Co

Sundeep Lal, Ph.D., MBA
Senior Director, New Products Licensing, Global Human Health,
Merck & Co.

Michael Liebman, Ph.D.
Chief Scientific Officer,
Windber Research Institute

Jann Nielsen, Ph.D.
Director, Project Management,
Wyeth Research

James Resch, Ph.D.
Director, Strategic Planning, Global Discovery Affairs, AstraZeneca

Jill Robinson, R.Ph., MBA
Vice President, Global Safety Surveillance & Epidemiology, Wyeth

Kim Slocum
Director, Strategic Planning & Business Development, AstraZeneca LP

Sean Zhao, Ph.D.
Director, Pharmacovigilance and Global Safety, Amgen Inc.

Partnership Programs

PSS Founding Partners


Cambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Cambridge Health Associates | Discovery On Target |
Health-IT World
| Bio-IT World Conference & Expo  | Molecular Medicine Tri-Conference | PEGS| PepTalk | Pharma DD
World Pharmaceutical Congress |

Your  Life Science Network

Cambridge Healthtech Institute  |  250 First Avenue  |  Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425